Eledon Pharmaceuticals' preclinical and Phase 1 studies, as well as our understanding of CD40 Ligand biology and historical data, have guided our choice of clinical development programs.

CD40L Pathway

The central role of CD40L signaling in generating pro-inflammatory responses makes it an attractive candidate for therapeutic intervention in autoimmune disease, induction and maintenance of transplant tolerance, and neuroinflammation.


AT-1501 is a humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. It was built around safety and engineered to maximize efficacy and half life.

Clinical Development

Eledon Pharmaceuticals is building upon our deep understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies in renal transplantation, islet cell transplantation, autoimmune nephritis, and amyotrophic lateral sclerosis (ALS).